Alluvi, known as BI 4744, offers a promising breakthrough in weight management treatment. This dual activator targeting both GLP-1 and GIP targets demonstrates remarkable effectiveness in research assessments, possibly https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/